500 patients67,039 observations150 daysLIVE

Patient P-03021

Synthetic patientONX-7 · Day 131 · 35–44 · M · baseline S15Open companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
51%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S15
  2. Day 100 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 100.

Primary contributors, last 14 days
  • GI instability-15
  • Nutritional resilience+12
  • Treatment adherence-11
  • Inflammatory activity-7
  • Toxicity+6

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    60%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 83% showed improvement
    • median effect visible after 8 days

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Butyrate / short-chain fatty acid production 80
      • MicrobiomeButyrate capacity 35/100
      • MicrobiomeF. prausnitzii depleted
      • Daily logFibre intake low in recent food logs
    • Drug metabolism and exposure 60
      • DNACYP2D6 poor metabolizer → higher exposure
      • BloodToxicity index 49
    • Mucosal barrier integrity 50
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • Daily logGI symptom score 52 and rising
    • Inflammatory signalling 40
      • BloodInflammatory load index 50
      • WearableHRV 35 ms, trending down
    • Autonomic recovery 20
      • WearableShort sleep window
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • CYP2D6 Poor metabolizer
      Higher exposure at standard dose
    Microbiome
    Shannon diversity 3 · butyrate capacity 35/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    37 ms
    Sleep
    6.1 h
    Steps
    7,249
    Resting HR
    67 bpm
    Daily log: GI score 52, nutritional resilience 47, adherence 69.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • Keep the current walking rhythm
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0346352%S11GI-04no change55
    P-0345147%S0862
    P-0303141%S16CR-01improved49
    P-0338241%S01GI-04improved56
    P-0322540%S19GI-04improved50
    P-0337940%S12GI-04improved51
    P-0328039%S1357
    P-0300438%S0356
    P-0346537%S17CR-01improved65
    P-0320136%S15GI-04improved68
    P-0328536%S0454
    P-0312035%S1461